Disease Prevalence and the Magnitude of Research Benefits

"Disease Prevalence and the Magnitude of Research Benefits." The American Journal of Bioethics, 18(4), pp. 73–74

This article refers to:

Ethical Guidance for Selecting Clinical Trials to Receive Limited Space in an Immunotherapy Production Facility

DISCLAIMER

The views expressed are the authors’ own. They do not represent the position or policy of the National Institutes of Health, U.S. Public Health Service, or the Department of Health and Human Services.

Notes

1. We do not rank prevalence relative to the other criteria Jecker and colleagues propose (equal opportunity, magnitude of medical benefit, resources required, and random selection) in part because we do not endorse the lexical priority Jecker and colleagues assign to each criterion in their system.